MC
MRNA icon

Moors & Cabot’s Moderna MRNA Stock Holding History

Moors & Cabot’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$1.65K – 912
2022
Q4 		$1.65K Buy
+300
New +$49.1K ﹤0.01% 847

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Moors & Cabot's MRNA Position: Q2 2026 in Review

Moors & Cabot increased its Moderna (MRNA) stake by 47% in Q2 2026, buying an estimated $243K and bringing the position to 14,616 shares worth $1.02M. The position accounts for 0.04% of the portfolio, ranked #382.

Moors & Cabot first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $15M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Moors & Cabot held 14,616 shares of Moderna worth $1.02M as of Q2 2026.
  • Moors & Cabot bought 4,700 Moderna shares in Q2 2026, an estimated $243K.
  • Moderna made up 0.04% of Moors & Cabot's portfolio in Q2 2026, its #382 holding.
  • Moors & Cabot first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Moors & Cabot's Moderna position peaked at $15M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.